- Home
- GYRE vs WLKP Comparison
GYRE vs WLKP Comparison
Compare GYRE & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- WLKP
- Stock Information
- Founded
- GYRE 2002
- WLKP 2014
- Country
- GYRE United States
- WLKP United States
- Employees
- GYRE N/A
- WLKP N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- WLKP Major Chemicals
- Sector
- GYRE Health Care
- WLKP Industrials
- Exchange
- GYRE Nasdaq
- WLKP Nasdaq
- Market Cap
- GYRE 997.3M
- WLKP 819.6M
- IPO Year
- GYRE N/A
- WLKP 2014
- Fundamental
- Price
- GYRE $11.54
- WLKP $24.18
- Analyst Decision
- GYRE
- WLKP
- Analyst Count
- GYRE 0
- WLKP 0
- Target Price
- GYRE N/A
- WLKP N/A
- AVG Volume (30 Days)
- GYRE 53.5K
- WLKP 35.1K
- Earning Date
- GYRE 03-25-2025
- WLKP 02-24-2025
- Dividend Yield
- GYRE N/A
- WLKP 7.79%
- EPS Growth
- GYRE N/A
- WLKP 8.66
- EPS
- GYRE N/A
- WLKP 1.75
- Revenue
- GYRE $105,033,000.00
- WLKP $1,143,109,000.00
- Revenue This Year
- GYRE $25.32
- WLKP N/A
- Revenue Next Year
- GYRE $12.95
- WLKP $5.56
- P/E Ratio
- GYRE N/A
- WLKP $13.83
- Revenue Growth
- GYRE N/A
- WLKP N/A
- 52 Week Low
- GYRE $8.26
- WLKP $21.19
- 52 Week High
- GYRE $26.37
- WLKP $24.98
- Technical
- Relative Strength Index (RSI)
- GYRE 47.99
- WLKP 54.49
- Support Level
- GYRE $12.09
- WLKP $23.40
- Resistance Level
- GYRE $12.80
- WLKP $24.98
- Average True Range (ATR)
- GYRE 0.56
- WLKP 0.35
- MACD
- GYRE -0.00
- WLKP -0.04
- Stochastic Oscillator
- GYRE 16.39
- WLKP 49.05
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develop ethyelene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.